Biosimilar competition saves US healthcare $21 billion
European Pharmaceutical Review
OCTOBER 14, 2022
Amgen’s 2022 market report has detailed how competition has driven savings across healthcare, estimating that a considerable number of biologics will be in competition with biosimilars in five to 10 years. A rise in savings per quarter was recognised in this year’s data.
Let's personalize your content